Функционально-метаболические изменения миокарда у больных в раннем постинфарктном периоде, их динамика под влиянием ингибитора ангиотензинпревращающего фермента (периндоприла) и цитопротектора (тримет
Диссертация
Для более эффективного лечения сердечной недостаточности II функционального класса (по классификации NYHA) у больных в раннем постинфарктном периоде рекомендуется в стандартную схему лечения включать наряду с ингибиторами ангиотензинпревращающего фермента препарат цитопротекторного действия (триметазидин) с целью оптимизации энергетического метаболизма ишемизированного участка миокарда, которая… Читать ещё >
Список литературы
- Ануфриева Е.Н., Бушмелев А. С., Тарловская А. И. Острая проба с триметазидином у больных в постинфарктном периоде // Тезисы докладов конференции по проблемам внезапной смерти. СПб, 1998. — С. 98.
- Ардашев В Н. Клинические варианты инфаркта миокарда. Стратификация осложнений и исходов: Автореф. дисс.. д-ра мед. наук. j"., 1990.-20 с.
- Афанасьева И.В., Мирошниченко А. Г. Антиишемический эффект предуктала и гемодинамические показатели в период проведения общехирургических операций // Конференция по внезапной смерти. Тезисы докладов. -СПб, 1998. С. 156.
- Бендер Н. (Bender N). Новые возможности препаратов, подавляющих активность ангиотензинпревращающего фермента// Тер. арх. -1982,-№ 9.-С. 101−103.
- Беленков Ю Н. Неинвазивные методы диагностики ишемической болезни сердца // Кардиология. 1996. — Т. 36. — № 1. — С. 4−11.
- Гиляровский С Р., Орлов В А., Гвинджилия Т В. Коррекция постинфарктного ремоделирования сердца ингибиторами ангиотензинпревращающего фермента // Кардиология. 1993. — № 12. — С. 37- 47.
- Домрадская А.И. Ишемическая болезнь сердца: цитопротекция миокарда // Клин, фармакол. и терапия. 1995. — № 4. — С. 66−67.
- Елисеев О М. Триметазидин (Предуктал). Новый подход в борьбе с ишемией миокарда // Тер. арх. 1996. — № 8. — С. 57−63.
- Кукеков В.Г., Фадеев Н. П. Позитронная эмиссионная томография (физико-технические аспекты)// Мед. радиол 1986 — Т. 31-№ 10.-С. 67−76.
- Либис Р.А., Код Я.И. Показатели качества жизни у больных с хронической сердечной недостаточностью // Кардиология. 1995. — № 11. — С.13−17.
- Литвинов М М. и др. ПЭТ при разных заболеваниях сердца у детей // Мед. радиол. 1996. — Т. 41. — № 1. — С. 32−35.
- Логиновская О.А., Цай Н.В., Шаталина Л. В., Перепеч Н. Б. Ан-тиангинальное, антиишемическое и антиоксидантное действие триметазидина у больных стенокардией // Тезисы докладов конференции по проблемам внезапной смерти. СПб, 1998. — С. 86.
- Маколкин В.И. Оценка региональной дисфункции миокарда и возможность коррекции с помощью предуктала (триметазидина) // Человек и лекарство Тезисы докладов VI Российский национальный конгресс -М&bdquo- 1999.
- Меерсон Ф.З. Патогенез и предупреждение стрессорных и ише-мических повреждений сердца. М.: Медицина, 1984. — 270 с.
- Метелица В.И. Современная фармакотерапия в кардиологии// Кардиология. 1997. — № 5. — С. 77−82.
- Оганов Р.Г., Марцевич С. Ю. Лекарственная терапия сердечнососудистых заболеваний: данные доказательной медицины и реальная клиническая практика // Рос. кардиол. журн. 2001. — № 4 (30). — С. 8−12.
- Пархоменко А.Е., Брыль Ж. В. Применение антиоксиданта триметазидина (Предуктала) в комплексной терапии острого инфаркта микар-да // Тер арх. 1996 — № 9. — С 47−52.
- Перепеч Н.Б. Прогнозирование недостаточности кровообращения у больных инфарктом миокарда // Тер. арх. 1983. — № 11— С. 21−24
- Преображенский Д.В., Сидоренко Б. А. Применение ингибиторов ангиотензинпревращающего фермента при лечении острого инфаркта миокарда // Кардиология. 1997. — № 3. — С. 100−104.
- Рябинин В.А., Голиков А. П., Руднев Д. В., Спасский А. А., Лукьянов М М. Влияние рамиприла на течение острого инфаркта миокарда // Кардиология. № 5. — С. 48−51.
- Савичева И.Ю., Рыжкова Д. В., Тютин Л. А. Применение ПЭТ с новым радиофармпрепаратом бутиратом натрия для оценки состояния миокарда у пациентов с ИБС // Вестн. рентгенол. 1999. — № 5. — С. 18 -21.
- Фишман Л.Я., Наркевич Б. Я. Современное состояние позитрон-ной эмиссионной томографии // Мед. радиол. 1994. — № 6. — С. 51−54.
- Фомин И., Белоусов С., Кубышева Н., Гальперин Е. Клиническая эффективность предуктала у больных стабильной стенокардией// Врач -1995 -№ 9. С. 15−16.
- Шиллер Н., Осипов М. А. Клиническая эхокардиография М Мир, 1993.-347 с.
- Aiayi A., Hoskiks N., Reid J L. Age and pharmacodinamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat// Brit J. Clin. Pharmacol. 1986. — Vol. 21. — P. 349−357.
- Astapie-Dequeker С., Joulin Y., Devynck M.A. Inhibitory effects of trimetazidine on thrombin-induced aggregation and calcium entry into human platalets // J. cardiovasc. Pharmacol. 1994. — Vol. 23. — № 3. — P. 401−407.
- Aussedat J., Ray A., Kay L., Verdus M., Harpey C., Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effects the antiischemic agent trimetazidine // J. cardiovasc. Pharmacol. 1993. -Vol. 21.-№ 1.-P. 128−135.
- Belcher P R., Drake-Holland A.J., Hynd J.W., Noble M.I. Effects of trimetazidine on in vivo coronary platelets thrombosis// Cardiovasc. Drugs Ther. 1993. — Vol. 7. — № 1. — P. 149−157.
- Boissel J.P. Free radicals, reperfusion and myocardial infartcion therapy: European Myocardial Infarction Project free radicals pilot study EMIP-FR Pilot Study Group // Europ. Heart J. — 1993. — Vol. 14 (Suppl. G). -P. 48−51.
- Boissel J.P., Bossard N. Ongoing clinical trials in acute coronary syndrome // Exp. Opin. Invest. Drugs. 1996. — Vol. 5. — № 5. — P. 567−572.
- Bolli R. Mechanism of myocardial «stunning» // Circulation. 1990. -Vcl. 82.-P. 723−738.
- Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overvier // Cardiovasc. Drugs Ther. 1991. — Vol. 5. — P. 249−268.
- Bolli R. Myocardial «stunning» in man// Circulation 1992 — Vol. 26.-P. 101−108.
- Braunwald E., Klonel R.A. The stunned myocardium, prolonged postishemic ventricular dysfunction// Circulation 1992 — Vol. 66 — P. 11 461 149.
- Brunken R.C., Schelbert H.R. Positron emission tomography in clinical cardiology // Clin. Cardiol 1989. — № 3. — P. 607−629.
- Broddeke E., Hustenburg J., Jap W., Heynis J., Van Zwieten P. New anti-ischemic drugs: cytoprotectine action with no primary hemodynamic effects // TIPS. 1989. — Vol. 10. — P. 397−400.
- Brottier L., Barat J.L., Combe C., Boussens В., Bonnet J., Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy // Europ. Heart J. 1990. — Vol. 11. — P. 207−212.
- Camilleri J.P., Joseph D. Effects of trimetazidine on experimental reperfused infarction in the rat // Europ. Heart J. 1988. — Vol. 9 (Suppl. 1). -Abstract 217.
- Canicave J.C. Determination en simple insu contre placebo de la relation dose/activite du Vastarel 20 mg dans l’insuffisante coronarienne chronique // Gaz. Med. France. 1980. — Vol. 87. — P. 5560−5563.
- Catroux P., Benchekroun N., Robert J., Cambar J. Influence of trimetazidine on deleterious effects of oxygen radical species in post-ischemic acute renal failure in the rat// Cardiovasc. Drugs Ther. 1990 — Vol.4 (Suppl. 4).-P. 816−817.
- Ceconi C., Cargnoni A., Pasini E., Codorelli E., Curello S., Ferrari R Evaluation of phospholipid peroxidation as malonedialdehyde during myocardial ischemia and reperfusion injury // Amer. J. Physiol. 1991. — Vol. 260. -P. 1057−1061.
- Charlon V., Boucher F., Clauser P. Effect of a 5-day trimetazidine pretreatment in model of ischemic and reperfused isolated rat heart, spin trapping experiments // Adv. exp. Med. Biol. 1990. — Vol. 264. — P. 377−382.
- Chierchia S.L., Fragasso G. Metabolic managment of ischemic heart disease // Europ. Heart J. 1993. — Vol. 14 (Suppl. G). — P. 2−5.
- Collins G., Marchant N., Breen M., Taylor A.R. The disposition, kinetics and metabolism of 14C-trimetazidine in Beagle dogs // Internal report. -1991.
- Collins G., Marchant N., Breen M., Taylor A.R. The disposition, kinetics and metabolism of 14C-trimetazidine in Cynomolgus monkeys// Internal report. 1991.
- Cruz J., Zaoui A., Ayoub S., Harpey C., Goupit P., Younes A. Alterations des myocytes isoles des ventricules de coeur de rat adulte: protection par la trimetazidine // Concours Med. 1987. — Vol. 36. — P. 3470−3475.
- D’Alche P. Electrocardiographical assessment of trimetazidine antiis-chemic properties // Cardiovasc. Drugs Ther. 1990. — Vol. 4. — P. 810−811.
- Danna-Volta S., Maraglino G., Delia-Valentina P., Viena P., Desideri A. Comparison of trimetazidine with nifedipine in effort angina, doubli-blind, cross-over study// Cardiovasc. Drugs Ther 1990 — Vol. 4.-P. 853−860.
- De Leiris J., Boucher F. Rationale for trimetazidine administration in myocardial ischemia-reperfusion syndrome// Europ. Heart J. 1993. — Vol. 14 (Suppl. G). — P. 34−40.
- Demaison L., Fantini E., Sentex E., Grynberg A., Athias P Trimetazidine: in vitro influence on heart mitochondrial function// Amer, J Cardiol 1995 -Vol. 76. -№ 6. -P. 31B-37B.
- Demer L.L., Gould K.L., Goldstein R.A. et al. Assisment of coronary artery disease severity by positron emission tomography / Comparison witch quantitative arteriography in 193 patients// Circulation 1989 — № 79 -P. 825−835.
- Detry J.M. Clinical features of an anti-anginal drug in angina pectoris // Europ. Heart J. 1993. — Vol. 14 (Suppl. G). — P. 18−24.
- Detry J.M., Leclercq P.J. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring// Amer. J. Cardiol 1995 — Vol. 76 -№ 6. — P. 8B-11B.
- Devynck M.A., Le Quan Sang K.H., Joulin Y., Mazeaud M. Acute membrane effects of trimetazidine in human platelets // Europ. J. Pharmacol. -1993. Vol. 245. — № 2. — P. 105−110.
- D’hahan N., Nathali H., Taouil K., Morel J. E. Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype// Brit. J. Pharmacol. 1998. — Vol. 123. — № 4. — P. 611−616.
- D’hahan N., Taouil K., Dassouli A., Morel J. E. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6// Europ. J. Cardiol. 1997. — Vol. 328. — № 2−3. — P. 163−174.
- Downey J.M., Latcham D.S., Walker J.M., Yellon D M. Adenosine and antiinfarct effects of preconditioning // Cardiovasc. Res. 1993. -Vol. 27. -P. 3−8.
- Drake-Holland A.J., Belcher P R., Hynd J., Noble M.I. Infarct size in rabbits, a modified method illustrated by the effects of propranolol and trimetazidine // Basic Res. Cardiol. 1993. — Vol. 88. — № 3. — P. 250−258.
- Editorial. Calcium antagonist cuation// Lancet. 1991. — Vol. 337. -P. 885−886.
- Elimadi A., Morin D., Sapena R., Chauvet-Monges A.M., Crevat A., Tillement J.P. Comparison of the effects of cyclosporine A and trimetazidine on Ca (2+)-dependent mitochondrial swelling// Fundam. clin. Pharmacol. 1997. -Vol. 11. -№ 5. — P. 440−447.
- Engler R.L. Adenosine. The signal of Life?// Circulation. 1991. -Vol. 84.-P. 951.
- Fabiani J.N., Ponzio O., Emerit I. Cardioprotective effect of trimetazidine during coronary artery graft surgery // J. cardiovasc. Surg. -1992. Vol. 33. — № 4. — P. 486−491.
- Fadeev N.P., Ryjkova D.V., Kostenikov N.A., Savello V.E., Mosto-va M.I. Sodium 1-C11. butyrate new diagnostic agent for PET // Supplement 1 to Journal of Labellet compaunds and radiopharmaphceuticals. — Vol. 44. — May 2001.-P. S310—S.312.
- Fantini E., Athias P., Demaison L., Grynberg A. Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat// Fundam. clin. Pharmacol. 1997. -Vol. 11. — № 5. — P. 427−439.
- Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetasidine on rat cardiomyocytes during hypoxia and reoxygenation // J. molec. Cell. Cardiol. 1994. — Vol. 26. -№ 8. — P. 949−958.
- Fay L., Michel G. Determination of trimetazidine in biological fluid by gaz chromatography mass spectrometry// J. Chromatogr — 1985 -Vol. 78. — P. 460.
- Ferrari R. The role of mitochondria in ischemic heart disease // J. cardiovasc. Pharmacol. 1996. — Vol 28 (Suppl. 1). — P. S1-S10.
- Ferrari R. The pole of free radicals in ischemic myocardium // Brit. J clin. Pract. 1990. — Vol. 44. — P. 301−305.
- Ferrari R. Importance of oxygen free radicals during ischemia and re-perfusion in the experimental and clinical setting // Amer. J. cardiovasc. Path. -1992.-Vol. 4.-P. 103−114.
- Ferrari R., Alfieri O., Curello S. Occurrence of oxidative stress during reperfusion of the human heart // Circulation. 1991. — Vol. 81. — P. 201−211.
- Ferrari R., Ceconi C., Curello S. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents// Amer J. Med 1991-Vol. 91. — P. 95−105.
- Ferrari R., Visioli O. Protective effects of calcium antagonists against ischemia and reperfusion damage // Drugs. 1991. — Vol. 42. — P. 14−27.
- Ferrari R., Visioli O. Stunning: damaging or protective to the myocardium? // Cardiovasc. Drugs Ther. 1991 — Vol. 5. — P. 939−946.
- Ferrari R. Commentary on hibernating myocardium and its clinical relevance // Basic Res. Cardiol. 1995. — Vol. 90. — P. 52−54.
- Frietas M. Ischemic symdrome: reperfusion and myocardial cytopro-tection//Rev. Port. Cardiol. 1997. — Vol. 16(Suppl. 11).-P. 925−931.
- Goidman L., Hashimoto В., Cook E.F., Locaizo A. Comparative re-prodicibility and validity of systems for assessing cardiovascular functional class: advantage of a new specific activity scale// Circulation 1981 -Vol. 44.-P. 1227−1234.
- Gould K.L., Mullani N.A. Routine clinical positron emission tomography for diagnostic cardiac imaging a review// Herz. — 1987 — № 12 -P. 13−21.
- Grandin C., Wiyns W., Melin J.A. et al. Delination of myocardial viability by PET // J. nucl. Med. 1995. — № 36(9). — P. 1543−1552.
- Granger C.B. Adenosine for myocardial protection in acute myocardial infarction // Amer. J. Cardiol. 1997. — Vol. 79. — № 12 — P. A44-A48.
- Greagh Т., Lanigan D., Murphy D., McLean P., Bouchier-Hayes D. Amelioration of cyclosporin-enhanced ischemic renal failure with trimetazidine // Brit. J. Surg. 1991. — Vol. 78. — P. 1493−1494.
- Greagh Т., Lanigan D., Dolan J., Tormey W., Walshe J.J., Bouchier-Hayes D. Pharmacological manipulation of acute cyclosporine ischemic renal injury with trimetazidine // J. Urol. 1993. — Vol. 149. — № 4. — P. 915−917.
- Grynberg A., Demaison L. Fatty acid oxidation in the heart // J. cardiovasc. Pharmacol. 1996. — Vol. 28 (Suppl. 1). — P. SI 1-S17.
- Guarnieri C., Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocro-taline-treated rats // Biochem. Pharmacol. 1988. — Vol. 24/ - P. 4685−4688.
- Guarniery C., Muscary C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in cardiac muscle // Cardiovasc. Drugs Ther. 1990. — Vol. 4 (Suppl. 4). — P. 814−815.
- Guarnieri C., Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium // Pharmacology. 1993. — Vol. 46 — № 6. — P. 324−331.
- Guarnieri C., Finelli C., Zini M., Muscari C. Effects of trimetazidine on the calcium transport and oxidative phosphorylation of isolated rat heart mitochondria // Basic Res. Cardiol. 1997. — Vol. 92. — № 2. — P. 90−95.
- Harpey C., Clauser P., Labrid G., Freyria J.L. Trimetazidine. A cellular anti-ischemic agent// Cardiovasc. Drugs Ther 1989 — Vol. 6.-№ 4.-P. 292−312.
- Harpey C., Coker S., Sellier P., Maccario J., Detry J.M. Permutation distribution estimation applied to the comparison of the profile of the activityof two antianginal drugs // Fundam. clin. Pharmacol. 1996. — Vol. 10. — № 2. -P. 151−155.
- Hearse D.J. Myocardial protection in ischemia and reperfusion: principles, problems and prospects // Medicographia. 1996. — Vol. 18. — № 2. -P. 22−29.
- Hearse D.J. Myocardial injury during ischemia and reperfusion: concepts and controversies // Myocardial Protection: The Pathophysiology of Reperfusion and Reperfusion Injury. New York: Ra 'en Press. — 1992. — P. 13−32.
- Hearse D.J. Ischemia, reperfusion and the determinants of tissue injury // Cardiovasc. Drugs Ther. — 1991 — Vol. 4. P. 767−776.
- Hearse D.J., Bolli R. Reperfusion-induced injury, manifestations, mechanisms and clinical relevance// Cardiovasc. Res 1992 — Vol. 26.-P. 101−108.
- Hearse D.J., Maxwell L., Saldanha C., Gavin J.B. The myocardial vasculature during ischemia and reperfusion: a target for injury and protection // J. molec. Cell. Cardiol. 1993. — Vol. 25. — P. 759−800.
- Hicks R.J., Herman W.H., Kalff V. et al. Quantitative evulation of regional substrate metabolism in the human heart by positron emission tomography // J. Amer. Coll. Cardiol. 1991. — № 18. — P. 101−111.
- Hisatome I., Ishiko R., Tanaka I., Kosaka H. Trimetasidine inhibits Na+, K+ATPase activity, and overdrive hyperpolarisation in guinea-pig ventricular muscle // Europ. J. Pharmacol. — 1991. Vol. 195. — P. 381−388.
- Hutchins G.D., Schwaiger M., Wolfe E. et al. Positron emission tomography to quan’itate myocardial perfusion // Amer. J. Cardiol. Imaging. -1993 -№ 4. -P. 283−293.
- Honore E., Adamantidis MM, Challice C.E. Cardioprotection by calcium antagonist, piridoxilate and trimetazidine// IRCS Med. Sci. 1986. -Vol. 14.-P. 938−939.
- Housset B. Etude de l’effet ptotecteur de la trimetazidine sur des cultures de cellules endothelials exposees a des radicaux libres extracellu-laires // Xth International Congress of Pharmacology. Sydney, 1987.
- Hustenburg J.G., Van Zweiten P.A., Jap T.J., Van Heiningen P.N., Bohnenn V. A. The cardioprotective effects of trimetasidine and nifedipine in guinea-pig hearts subjected to global ischemia// Brit. J. Pharmacol 1989 -Vol. 96.-P. 199.
- Jackson G. Angina, myocardial hibernation and trimetazidine// Int. J. clin. Pract 1997. -Vol. 51-№ 6.-P. 347.
- Jackson P.J., Brownsill D., Taylor A.R., Resplandy G" WaltherB., Schweitert H.R. Identification of trimetazidine metabolites in human urine and plasma // Xenobiotica. 1996. — Vol. 26. — № 2. — P. 221−228.
- Jenning R.B., Murry C.E., Steenberger C., Reimer K.A. Development of cell injury in sustained acute ischemia// Circulation 1990 -Vol. 82.-P. II 2-II 12.
- King L.M., Boucher F., Opie L.H. Coronary flow and glucose delivery as determinants of contracture in the ischemic myocardium adenosine // J. molec. Cell. Cardiol. 1995. — Vol. 27. — P. 701−720.
- Kiyosue Т., Nakamura S., Akita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes // J. molec. Cell. Cardiol. 1986. — Vol. 18.-P. 1301−1311.
- Kober G., Buck Т., Sievert H., Vallbracht C. Direct antiischemic effect of trimetazidine during coronary angioplasty (PTCA) // Circulation. -1990 -Vol. 82.-P. 1119.
- Kober G., Buck Т., Sievert H., Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty, effect of trimetazidine // Europ. Heart J 1992 -Vol. 13- № 8. -P. 1109−1115.
- Koning M M., Krams R., Xiao C.S., Van Meegen J R. Intracoronary trimetazidine does not improve recovery of the regional function in a porcine model of repeated ischemia// Cardiovasc. Drugs Ther- 1993 Vol. 7.-№ 5. — P. 801−807.
- Kubler W., Haass M. Cardioprotection: definition, classification and fundamental principles // Heart. 1996. — Vol. 75. — P. 330−333.
- Lagadis-Gossman D., Le Prigent K., Feuvray D. Effects of trimetazidine on pH regulation in the rat isolated ventricular myocyte // Brit. J. Pharmacol. 1996. — Vol. 117. — № 5. — P. 831−838.
- Lavanchy N., Martin J., Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart// Arch. int. Pharmacodyn. Ther. 1987. — Vol. 286. — P. 97−110.
- Levy S. and the Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease // Amer. J. Cardiol. 1995. — Vol. 76. — № 6. — P. 12B-17B.
- Libersa С., Honorc E., Adamantidis M., Rouet E., Dupuis B. Antiischemic effects of trimetazidine: enzymatic and electric response in a model of in vitro myocardial ischemia// Cardiovasc. Drugs Ther. 1990. -Vol. 4 (Suppl. 4). — P. 808−809.
- Lopaschuk G.D., Stanley W.C. Glucose metabolism in the ischemic heart // Circulation. 1997. — Vol. 95. — P. 313−315.
- Manchanda S.C., Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris// Heart '^97-Vol. 78,-№ 4.-P. 353−357.
- Marber M.S., Latcham D.S., Walker J.M., Yellon D M. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction// Circulation 1993 — Vol. 88 -P. 1264−1272.
- Maridonneau-Parini I., Harpey C. Trimetazidine protects the human red blood cell aganst oxygen free radical damage // Cardiovasc. Drugs Ther. -1990. Vol. 4 (Suppl. 4). — P. 818−819.
- Maupoil V., Rochette L., Tabard A., Clauser P., Harpey C. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart // Cardiovasc. Drugs Ther. 1990. — Vol. 4. — P. 791−796.
- Mazeri A. Ischemic Heart Disease. London: Churchill Livingstone, 1995.
- McGovern P.G., Pankow J.S., Shahar E. Recent trends in acute coronary heart disease //NewEngl. J. Med. 1996. — Vol. 334. — P. 884−890.
- Michaelidis A.P., Vissoulis G.P., Bonoris P.E., Psaros Т.К., Papadopoulus P.D., Toutouzas P.K. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment// Curr. Ther. Res 1989 -Vol. 46. — P. 565−576.
- Michel G., Fay L., Goupit P., Harpey C., Prost M. Simple method for the measurement of trimetazidine in human plasma using gaz chromatography with nitrogen selective detection // Internal report. 1989.
- Miyata H., Lakatta E.G., Stern M.D., Silverman H.S. Relation of mitochondrial and citosolic free calcium to cardiac recovery after exposure to anoxia // Circulat. Res. 1992. — Vol. 71 — P. 605−613.
- Mody F.W., Schelbert H., Coyle K. Mechanism of action of novel metabolically active antianginal agent (trimetazidine) delineated by PET// J. Amer. Coll. Cardiol. 1996. — Vol. 27 (Suppl. A). — P. 934−942.
- Monpere C., Brochier M., Demange J., Ducloux G., Warin J.F. Combination of trimetazidine with nifedipine in effort angina// Cardiovasc Drugs. Ther. 1990. — Vol. 4. — P. 824−825.
- Morin C., Didier G.J., Elimadi A., Aziz K. Evidence for existence of 3H.-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore // Brit. J. Pharmacol. 2000. — Vol. 123. — P. 13 851 394.
- Mullane K., Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine// J. molec. cell. Cardiol. 1995. — Vol. 27. — P 1041−1054.
- Muller-Suur R., Odlind В., Landelius J. Intravenous lidoflazine in healthy volonteers // Drug Invest. 1991. — Vol. 3. — P. 91−92.
- Murray C.E., Jenning R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury inischemic myocardium // Circulation. -1986.-Vol. 74.-P. 1124−1136.
- Noble M.I., Belcher P R., Drake-Holland A.J. Limitation of infarct size by trimetazidine in the rabbit // Amer. J. Cardiol. 1995. -Vol. 76. — № 6. -P. 41B-44B.
- Oliver M.F., Opie L.H. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias // Lancet. 1994. — Vol. 343. — P. 155−158.
- Oosterhuis В., Jonkman J.H.G., Bengelink J.K. Study of the relationship between the pharmacokinetics of trimetazidine and the dose taken per os // Pharmacology Bio-Research report. 1989.
- Opie L.H., Boucher F. Trimetazidine and myocardial ischemic contracture in isolated rat heart// Amer. J. Cardiol. 1995. — Vol. 76. — № 6. -P 38B-40B.
- Papadopoulos C.L., Kanonidis I.E., Kotridis P. S., Papayannis I.L. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction // Int. J. Cardiol. 1996. — Vol. 55. — № 2. — P. 137−142.
- Parkinson F.E., Clanachan A S. Adenosine receptors and nucleoside transport sites in cardiac cells// Brit. J. Pharmacol 1991- Vol. 104.-P. 398−401.
- Parratt J R. Cardioprotection by angiotensin converting-enzyme inhibitors- the experimental evidens// Cardiovasc. Res 1994 — Vol. 28 -P. 183−189.
- Passeron J. Efficacy of trimetazidine in stable effort angina. Double-blind study against placebo // Presse med. 1986. — Vol. 15. — P. 1775−1778.
- Perletti G., Monti E., Paracchini L., Piccinini F. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity // Arch. int. Pharma-codyn. 1989. — Vol. 302. — P. 280−289.
- Perdigao C. Acute myocardial infarction and left ventricular disfunction // Acta med. Port. 1996. — Vol. 9. — P. 113−119.
- Pornin M. Lack of effects of trimetazidine on systemic hemodynamic // Clin. Trials Metaanal. 1994. — Vol. 29. — P. 49−56.
- Pornin M., Harpey C., Allal J., Ourbak P. Effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease // J. molec. cell. Cardiol. 1990. — Vol. 22 (Suppl. 22). — P. 150.
- Przyklenk K., Klonel R.A., Yellon D M. Ischemic Preconditioning The Concept of Endogenous Cardioprotection. Kluver, Boston, — 1994.
- Rahimtoola S.H. The hibernating miocardium// Amer. Heart J -1989. Vol. 117. — P. 211−221.
- Rahman F., Toshima Y., Kohno H., Kinoshita K., TokunagaK. The protective effects of trimetazidine on normothermic ischemic myocardiu in rats // Jap. J. Surg. 1989. — Vol. 19. — № 3. — P. 346−350.
- Renaud J.F. Le controle du pH intracelllulaire par le trimetazidine previent l’accumulation de Na+ and Ca2+ dans le cellule cardiaque au cours del’acidose // Concours med. J 987. — Vol. 36. — P. 3463−3469.2+
- Renaud J.F. Internal pH, Na and Ca regulation by Trimetazidine during cardiac cell acidosis// Cardiovasc. Drugs Ther. 1988 — Vol.1 -P 677−686.
- Ribeiro C. Therapeutic application of myocardial cytoprotection// Riv. Port. Cardiol. 1994. — Vol. 13. — P. 669−670.
- Rona G. Catecholamine cardiotoxity// J. molec. cell. Cardiol.-1985 -Vol. 17.-P. 291.
- Rossi A., Lavanchi N., Martin J. Anti-ischemic effects of trimetazidine P-NMR spectroscopy study in the isolated rat heart // Cardiovasc. Drugs Ther. 1990. — Vol. 4 (Suppl. 4). — P. 812−813.
- Ruiz-Meana M., Garcia-Dorado D., Julia M., Gonzalez M. A., In-serte J., Soler-Soler J. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes// Cardiovasc. Res. 1996. -Vol. 32. -№ 3. — P. 587−592.
- Salducci A.M., Chauvet-Monges A.M., Tillement J.P. Trimetazidine reverses calcium accumulation and impairment of ATP synthesis induced by cyclosporine in isolated rat liver mitochondria// J. Pharmacol, exp. Ther.-1996. Vol. 277. — № 1. — P. 417−422.
- Schelbert H., Czernin J. Cardiologic applications of positron emission tomography II Wien. klin. Wschr. 1994. — № 15. — P. 487−495.
- Schoebel F.C., Frazier O.H., Jessurun G.A.J., De Jongste M.J.L., Kadipasaoglu K.A., Jax T.W. Refractory angina pectoris in end-stage coronary artery disease: Evolving therapeutic concepts// Heart 1997 — Vol. 134 -№ 4. — P. 587−602
- Scholz W., Albus U. Potential of selective sodium-hydrogen exchange inhibitors in cardiovascular therapy // Cardiovasc. Res 1995. — Vol. 29.-P. 184−188.
- Schrader J. Adenosine. A homeostatic metabolite in cardiac energy metabolism // Circulation. 1990. — Vol. 81 — P 389−390.
- Schwaiger M., Sun D., Deeb N. Expression of myocardial glucose transporter (GLUT) mRNAs in patients with advanced coronary artery disease // Circulation. 1994. — Vol. 90. — № 4. — P. 113.
- Schwaiger M. Miocardial perfusion imaging with PET// J. nucl. Med. 1994. — № 4. P. 693−698.
- Sedlak J., Lindsay R.H. Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissue with Ellman’s reagent// Analyt. Bio-chem. 1968. — Vol. 25. — № 1−3. — P. 192−205.
- Sellier P., Audouin P., Payen В., Cormier P., Duong T.C., Ourbak P Acute effects of trimetazidine evaluated by exercise testing// Europ. J. clin. Pharmacol. 1987. — Vol. 33. — P. 205−207.
- Sellier P., Maurice P. Recherche des effects hemodynamques de la trimetazidineen administration unique chez l’homme// Therapie. 1987. — Vol. 42. — P. 245−246.
- Sentex E., Sergiel J.P., Lucien A., Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte // Molec. cell. Biochem.2000. Vol. 175. -№ 1−2. — P. 153−162.
- Shirohase H., Suzuki Y., Kinitomo K., Osumi S., KaketaniN. Antiplatelet action of trimetasidine dihydrochloride (Vastarel): relation of arachidonic acid release inhibitory actions// J. med. Pharmacol. Sci. 1987. -Vol. 18.-P. 1025−1031.
- Shirohase H" Suzuki Y., Osumi S., Kakeya N., Kurahashi К Inhibitory effects of trimetasidine dihydrochloride on aggregation, serotonin release and malonedialdehyde production in rabbit platelets // Jap. J Pharmacol. 1988. — Vol. 47. — P. 29−34.
- Stanley W.C., Lopaschuk G.D., Hall J.L., McCormackJ. G Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions // Cardiovasc. Res.2001. Vol. 33. — № 2. — P. 243−257.
- Sullivan B.A., Hak L.J., Finn F.W. Cyclosporin nephrotoxicity: studies in laboratory animals // Transplant. Proc. 1985. — Vol. 17 — P. 145— 150.
- Tamaki N., Kawamoto M., Tadamura E. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography // Circulation. 1995. — Vol. 91. — P. 1697−1705.
- Tellier P. Trimetazidine: from cytoprotective effect to anti-ischemic efficacy // Medicographia. 1996. — Vol. 18. — № 2. — P. 46−50.
- Timour Q., Harpey С, Durr F., Faucon G. Is the antianginal action of trimetasidine independent of hemodinamic changes? // Cardiovasc. Drugs Ther 1991-Vol. 5.-P. 1043−1044.
- Tillement J.P., Crevat A., Testa В., Le Ridant A. Pharmacological modulation of mitochondrial oxidative phosphorylation, inhibition by cyclosporin A, restoration by trimetazidine // Ann. Pharmac. Franc. 1996. — Vol. 54. -№ 6.-P. 268−271.
- Van Bell H., Wynants J., Ver Donck K. Prevention of catecholamine-induced damage and death with a nucleoside transport inhibitor // J. cardiovasc. Pharmacol. 1992. — Vol. 20. — P. 73.
- Vatner S.F., Heyndrickx G.R. Ubiqity of myocardial stanning// Basic Res. Cardiol. 1995. — Vol. 90. — P. 253−256.
- Veitch K., Maisin L., Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion// Amer. J. Cardiol. 1995. — Vol. 76. — № 6. — P. 25B-30B.
- Wallace D., Breen M., Brownsill R.D., Taylor A.R. The metabolism of trimetazidine in man // Internal report. 1991.
- Williams F.M., Tanda K., Kus M., Williams T.J. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits // J. cardiovasc. Pharmacol. 1993. — Vol. 22. — № 6. — P. 828−833.
- Yellon D M. Latchman D.S. Stress proteins and myocardial protection during ischemia and reperfusion// Myocardial Protection: The Pathophysiology of Reperfusion and Reperfusion Injury. New York: Raven Press, 1992.-P. 185−195.
- Zarco P., Zarco Vol. H. Biochemical aspects of cardioprotection// Medicographia. 1996 — Vol. 18.-№ 2.-P. 18−21.
- Zhao Z.Q., Nakanishi K., Scott McGee D., Tan P., Vinter-Johan-cenJ. Al receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischemia// Cardiovasc. Res 1994 -Vol. 28. — P. 270−279.